Bis(2,6-dioxopiperazines), catalytic inhibitors of DNA topoisomerase II, as molecular probes, cardioprotectors and antitumor drugs

Biochimie

Volumn 80, Issue 3, 1998, Pages 235-246

  Andoh, T ^a  

^a SOKA UNIVERSITY   (Japan)

Author keywords

Bis(dioxopiperazine); Catalytic inhibitor; Cleavable complex; Dioxopiperazine; ICRF; MST 16; Topoisomerase

Indexed keywords

1,2 BIS(3,5 DIOXOPIPERAZIN 1 YL)ETHANE; 2 FLUORO 1 (3 NORVALYLAMINO 1 PYRROLIDINYL) 4 OXO 4H QUINO[8,1A,1 B,C][1,4]BENZOXAZINE 5 CARBOXYLIC ACID; ACLARUBICIN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BIS(2,6 DIOXOPIPERAZINE) DERIVATIVE; CHLOROQUINE; DAUNORUBICIN; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; FOSTRIECIN; GYRASE INHIBITOR; INTOPLICINE; MERBARONE; NOVOBIOCIN; PIPERAZINE DERIVATIVE; RAZOXANE; SN 22995; SOBUZOXANE; SURAMIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CARDIOTOXICITY; CHROMOSOME SEGREGATION; DNA REPLICATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; HEART PROTECTION; HUMAN; LYMPHOMA; MOLECULAR PROBE; NONHUMAN; REVIEW; T CELL LEUKEMIA;

EID: 0032033343     PISSN: 03009084     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-9084(98)80006-0     Document Type: Article

References (96)

1. 1 Chen AY, Liu LF (1994) DNA topoisomerases: Essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 34, 191-218
2. 2 Froelich-Ammon SJ, Osheroff N (1995) Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J Biol Chem 270, 21429-21432
3. 3 Beck WT, Danks MK (1991) Multidrug resistance associated with alterations in topoisomerase II. In: DNA Topoisomerases in Cancer (Potmesil M, Kohn K, eds) Oxford Univ Press, NewYork, 260-275
4. 4 Chen M, Beck WT (1993) Teniposide-resistant CEM cells, which express mutant DNA topoisomerase IIα, when treated wtih non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Res 53, 5946-5953
5. 5 Jensen PB, Sørenson BS, Demant EJF, Sehested M, Jensen PS, Vindelov L, Hansen HH (1990) Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino)methanesulfon-manisideide in human small cell lung cancer cell lines and on topoisomerae II-mediated DNA cleavage. Cancer Res 50, 3311-3316
6. 6 Drake FH, Hofmann GA, Mong SM, Bartus JO, Hertzberg RP, Johnson RK, Mattern MR, Mirabelli CK (1989) In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbgarone. Cancer Res 49, 2578-2583
7. 7 Boritzki TJ, Wolfard TS, Besserer JA, Jackson RC, Fry DW (1988) Inhibition to type II topoisomerase by fostriecin. Biochem Pharmacol 37, 4063-4068
8. 8 Jensen PB, Jensen PS, Demant EJF, Friche E, Sørensen BS, Sehested M, Wassermann K, Vindeloev L, Westergaard O, Hansen HH (1991) Antagonistic effect of aclarubicin on daunorubicin-incuced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. Cancer Res 51, 5093-5099
9. 9 Bojanowski K, Lelievre S, Markovits J, Coupree J, Jacquemin-Sablon A, Larsen AK (1992) Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Proc Natl Acad Sci USA 89, 3025-3029
10. 10 Permana PA, Snapka RM, Shen LL, Chu DTW, Clement JJ, Plattner JJ (1994) Quinobenoxazines: a class of novel antitumor quinolones and potent mammalian DNA topoisomerase II catalytic inhibitors. Biochemistry 33, 11333-11339
11. 11 Tanabe K, Ikegami Y, Ishida R, Andoh T (1991) Inhibition of topoisomerase II by antitumor agents bis(2, 6-dioxopiperazine) derivatives. Cancer Res 51, 4903-4908
12. 12 Ishida R, Miki T, Narita T, Yui R, Sato M, Utsumi KR, Tanabe K, Andoh T (1991) Inhibition of intracellular topoisomerase II by antitumor bis(2, 6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res 51, 4909-4916
13. 13 Jensen PB, Sørensen BS, Sehested M, Grue P, Demant EJF, Hansen HH (1994) Targeting the cytotoxicity of topoisomrase II-directed epipodophyllotoxins to tumor cells in acidic environments. Cancer Res 54, 2959-2963
14. 14 Utsumi H, Shibuya ML, Kosaka T, Buddenbaum WE, Elkind MM (1990) Abrogation by novobiocin of cytotoxicity due to the topoisomerase II inhibitor amsacrine in Chinese hamster cells. Cancer Res 50, 2577-2581
15. 15 Osheroff N (1989) Biochemical basis for the interactions of type I and type II topoisomerases with DNA. Pharmacol Ther 41, 223-241
16. 16 Watt PM, Hickson ID (1994) Structure and function of type II DNA topoisomerases. Biochem J 303, 681-695
17. 17 Roca J (1995) The mechanism of DNA topoisomerases. TIBS 20, 156-160
18. 18 Berger JM, Gamblin SJ, Harrison SC, Wang JC (1996) Structure and mechanism of DNA topoisomerase II. Nature 379, 225-232
19. 19 Wang JC (1996) DNA topoisomerases. Annu Rev Biochem 65, 635-692
20. 20 Creighton AM, Hellmann K, Whitecross S (1969) Antitumour activity in a series of bisDiketopiperazines. Nature 222, 384-385
21. 21 Hellmann K, Newton KA, Whitmore DN, Hanham IWF, Bond JV (1969) Preliminary clinical assessment of ICRF-159 in acute leukaemia and lymphosarcoma. Br Med J 1, 822-824
22. 22 Herman EH, Witiak DT, Hellmann K, Waravdekar VS (1982) Biological properties of ICRF-159 and related bis(dioxopiperazine) compounds. Adv Pharmacol Chemother 19, 249-290
23. 23 Creighton AM, Birnie GD (1969) The effect of bisdioxopiperazines on the synthesis of deoxyribonucleic acid, ribonucleic acid and protein in growing mouse embryo fibroblasts. Biochem J 114, 58P
24. 24 Sharpe HBA, Field EO, Hellmann K (1970) Mode of action of the cytostatic agent 'ICRF-159'. Nature 226, 524-526
25. 25 Hallowes RC, West DG, Hellmann K (1974) Cumulative cytostatic effect of ICRF-159. Nature 247, 487-491
26. 26 Witiak DT, Lee HJ, Hart RW, Gibson RE (1977) Study of trans-cyclopropylbis(diketopiperazine) and chelating agents related to ICRF 159. Cytotoxocity, mutagenicity, and effects on scheduled and unscheduled DNA synthesis. J Med Chem 20, 630-635
27. 27 Roca J, Ishida R, Berger JM, Andoh T, Wang JC (1994) Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 91, 1781-1785
28. 28 Witiak DT, Wei Y (1990) Dioxopiperazines: Chemistry and biology. Progr Drug Res 35, 249-363
29. 29 Ishimi Y, Ishida R, Andoh T (1992) Effect of ICRF-193, a novel DNA topoisomerase II inhibitor, on Simian virus 40 DNA and chromosome replication in vitro. Mol Cell Biol 12, 4007-4014
30. 30 Ishimi Y, Ishida R, Andoh T (1995) Synthesis of Simian virus 40 C-family catenated dimers in vivo in the presence of ICRF-193. J Mol Biol 247, 835-839
31. 31 Ishida R, Hamatake M, Wasserman RA, Nitiss JL, Wang JC, Andoh T (1995) DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae. Cancer Res 55, 2299-2303
32. 32 Sato M, Ishida R, Ohsumi K, Narita T, Andoh T (1997) DNA topoisomerase II as the cellular target of a novel antitumor agent ICRF-193, a bisdioxopiperazine derivative, in Xenopus egg extract. Biochem Biophys Res Commun 235, 571-575
33. 33 Adams DE, Shekhetman EM, Zechiedrich EL, Schmid MB, Cozzarelli NR (1992) The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replication. Cell 71, 277-288
34. 34 DiNardo S, Voelkel K, Sternglanz R (1984) DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication. Proc Natl Acad Sci USA 81, 2616-2620
35. 35 Caron PR, Watt P, Wang JC (1994) The C-terminal domain of Saccharomyces cerevisiae DNA topoisomerase II. Mol Cell Biol 14, 3197-3207
36. 36 Snapka RM, Permana PA (1993) SV40 DNA replication intermediates: analysis of drugs which target mammalian DNA replication. BioEssays 15, 121-127
37. 37 Permana PA, Ferrer CA, Snapka RM (1994) Inverse relationship between catenation and superhelicity in newly replicated simian virus 40 daughter chromosomes. Biochem Biophys Res Commun 201, 1510-1517
38. 38 Ishimi Y, Sugasawa K, Hanaoka F, Eki T, Hurwitz J (1992) Topoisomerase II plays an essential role as a swivelase in the late stage of SV40 chromosome replication in vitro. J Biol Chem 267, 462-466
39. 39 Sato M, Ishida R, Narita T, Kato JI, Ikeda H, Andoh T (1997) Interaction of DNA topoisomerase II catalytic inhibitor ICRF-193, a bisdioxopiperazine derivative, with conserved region(s) of eukaryotic but not prokaryotic enzyme. Biochem Pharmacol 54, in press
40. 40 Hasinoff BB, Kuschak TI, Yalowich JC, Creighton AM (1995) A qsar study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (Dexrazoxane). Biochem Pharmacol 50, 953-958
41. 41 Kim RA, Wang JC (1989) Function of DNA topoisomerases as replication swivels in Saccharomyces cerevisiae. J Mol Biol 208, 257-267
42. 42 Yang L, Wold MS, Li JJ, Kelly TJ, Liu LF (1987) Roles of DNA topoisomerases in simian virus 40 DNA replication in vitro. Proc Natl Acad Sci USA 84, 950-954
43. 43 Aveman K, Knippers R, Koller T, Sogo JM (1988) Camptothecin, a specific inhibitor of type 1 DNA topoisomerase, induces DNA breaks at replication forks. Mol Cell Biol 8, 3026-3034
44. 44 Sundin O, Varshavsky A (1980) Terminal stages of SV40 DNA replication proceed via multiply intertwined catenated dimers. Cell 21, 103-114
45. 45 Brush GS, Kelly TJ, Stillman B (1995) Identification of eukaryotic DNA replication proteins using simian virus 40 replication system. Methods Enzymol 262, 522-548
46. 46 Takasuga Y, Andoh T, Yamashita J, Yagura T (1995) ICRF-193, an inhibitor of topoisomerase II, demonstrates that DNA replication in sperm nuclei reconstituted in Xenopus egg extracts does not require chromatin decondensation. Exp Cell Res 217, 378-384
47. 47 Holm C, Goto T, Wang JC, Botstein D (1985) DNA topoisomerase II is required at the time of mitosis in yeast. Cell 41, 553-563
48. 48 Uemura T, Yanagida M (1986) Mitotic spindle pulls but fails to separate chromosomes in type II DNA topoisomerase mutants: uncoordinated mitosis. EMBO J 5, 1003-1010
49. 49 Ishida R, Sato M, Narita T, Utsumi KR, Nishimoto T, Morita T, Nagata H, Andoh T (1994) Inhibition of DNA topoisomerase II by ICRF-193 induces polypoidization by uncoupling chromosome dynamics from other cell cycle events. J Cell Biol 126, 1341-1351
50. 50 Andoh T, Sato M, Narita T, Ishida R (1993) Role of DNA topoisomerase II in chromosome dynamics in mammalian cells. Biotechnol Appl Biochem 18, 165-174
51. 51 Uemura T, Ohkura H, Adachi Y, Morino K, Shiozaki K, Yanagida M (1987) DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S pombe. Cell 50, 917-925
52. 52 Giménez-Abián JF, Clarke DJ, Mullinger AM, Downes CS, Johnson RT (1995) A postprophase topoisomerase II-dependent chromatid core separation step in the formation of metaphase chromosomes. J Cell Biol 131, 7-17
53. 53 Anderson HJ, Roberge M (1992) DNA topoisomerase II: a review of its involvement in chromosome structure, DNA replication, transcription and mitosis. Cell Biol Int Rep 16, 717-724
54. 54 Inazawa J, Ariyama T, Tokino T, Tanigami A, Nakamura Y, Abe T (1994) High resolution ordering of DNA markers by multi-color fluorescent in situ hybridization of prophase chromosomes. Cytogenet Cell Genet 65, 130-135
55. 55 Ariyama T, Kimura T, Yamakawa K, Nakamura Y, Abe T, Inazawa J (1995) Precise ordering of 26 cosmid markers on chromosome region 3p23-p21.3 by two-color FISH on human prophase chromosomes and stretched DNAs. Cytoget Cell Genet 70, 129-133
56. 56 Clarke DJ, Johnson RT, Downes CS (1993) Topoisomerase II inhibition prevents anaphase chromatid segregation in mammalian cells indepenently of the generation of DNA strand breaks. J Cell Sci 105, 563-569
57. 57 Gorbsky GJ (1994) Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane; ADR-529] and ICRF-159 (Razoxane). Cancer Res 54, 1042-1048
58. 58 Hartwell LH, Weinert TA (1989) Checkpoints: conttrols that ensure the order of cell cycle events. Science 246, 629-634
59. 59 Downes CS, Clarke DJ, Mullinger AM, Gimenez-Abian JF, Greighton AM, Johnson RT (1994) A topoisomerase II-dependent G2 cycle checkpont in mammalian cells. Nature 372, 467-470
60. 60 Iwai M, Hara A, Andoh T, Ishida R (1997) ICRF-193, a catalytic inhibitor of DNA topoisomerase II, delays the cell cycle progression from metaphase, but not from anaphase to the G1 phase in mammalian cells. FEBS Lett 406, 267-270
61. 61 Rieder CL, Schultz A, Cole R, Sluder G (1994) Anaphase onset in vertebrate somatic cells is controlled by a checkpoint that monitors sister kinetochore attached to the spindle. J Cell Biol 127, 1301-1310
62. 62 Li X, Nicklas RB (1995) Mitotic forces control a cell-cycle checkpoint. Nature 373, 630-632
63. 63 Sørensen BS, Sinding J, Andersen AH, Alsner J, Jensen PB, Westergaard O (1992) Mode of action of topoisomerase II-targeting agents at a specific DNA sequence: Uncoupling the DNA binding, cleavage and religation events. J Mol Biol 228, 778-786
64. 64 Woynarowski JM, Sigmund RD, Beerman TA (1989) DNA minor groove binding agents interfere with topoisomerase II mediated lesions induced by epipodophyllotoxin derivative VM-26 and acridine derivative m-AMSA in nuclei from L1210 cells. Biochemistry 28, 3850-3855
65. 65 Sehested M, Jensen PB (1996) Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem Pharmacol 51, 879-886
66. 66 Kawada SZ, Yamashita Y, Fujii N, Nakano H (1991) Induction of a heat-stable topoisomerase II-DNA cleavable complex by nonintercalative terpenoides, terpentecin and clerocidin. Cancer Res 51, 2922-2925
67. 67 Kano Y, Narita T, Suzuki K, Akutsu M, Suda K, Sakamoto S, Miura Y (1992) The effects of ICRF-154 in combination with other anticancer agents in vitro. Br J Cancer 66, 281-286
68. 68 Ishida R, Iwai M, Hara A, Andoh T (1996) The combination of different types of antitumor topoisomerase II inhibitors, ICRF-193 and VP-16, has synergistic and antagonistic effects on cell survival, depending on treatment schedule. Anticancer Res 16, 2735-2740
69. 69 Rhomberg WU (1978) Radiotherapy combined wtih ICRF 159 (NSC 129943). Int J Rad Oncol Biol Phys 4, 121-126
70. 70 Taylor IW, Bleehen NM (1977) Interaction of ICRF 159 with radiation, and its effect on sub-lethal and potentially lethal radiation damage in vitro. Br J Cancer 36, 493-500
71. 71 Woodman RJ, Cysyk RL, Kline K, Gang M, Venditti JM (1975) Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-129943). Cancer Chemother Rep 159, 689-695
72. 72 Holm B, Jensen PB, Sehested M (1996) ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors. Cancer Chemother Pharmacol 38, 230-209
73. 73 Speyer JL, Green MD, Zelenius-Jacquotte A, Wernz JC, Rey M, Sanger J, Kramer K, Ferrans V, Hochster H, Meyers M, Blum RH, Feit F, Attubato M, Burrows M, Muggia FM (1992) ICRF-187 permits longer treatment with doxorubicin in woman with breast cancer. J Clin Oncol 10, 117-127
74. 74 Herman EH, Ferrans VJ (1987) Amelioration of chronic anthracycline cardiotoxicity by ICRF-187 and other compounds. Cancer Treat Rep 14, 225-229
75. 75 Salsbury AJ, Burrage K, Hellmann K (1970) Inhibition of metastatic spread by ICRF 159: selective deletion of a malignant characteristic. Br Med J 4, 344-346
76. 76 Witiak DT, Lee HJ, Goldman HD, Zwilling BS (1978) Stereoselective effects of cis-and trans-cyclopropylbis(dioxopiperazines) related to ICRF-159 on metastases of a hamster lung adenocarcinoma. J Med Chem 21, 1194-1197
77. 77 Hellmann K, Gilbert J, Evans M, Cassell P, Taylor R (1987) Effect of razoxane on metastases from colorectal cancer. Clin Exp Metastasis 5, 3-8
78. 78 Cai JC, Shu HL, Tang CF, Komatsu T, Matsno T, Narita T, Yamaguchi S, Koide Y, Takase M (1989) Synthesis and antitumor properties of N1-acyloxymethyl derivatives of bis(2,6-dioxopiperazines). Chem Pharm Bull 37, 2976-2983
79. 79 Narita T, Yaguchi S, Komatsu T, Takase M, Hishino A, Inaba M, Tsukagoshi S (1990) Antitumor activity of MST-16, a novel derivative of bis(2,6-dioxopiperazine), in murine tumor models. Cancer Chemother Pharmacol 26, 193-197
80. 80 Narita T, Koide Y, Yaguchi S, Kimura S, Izumisawa Y, Takase M, Inaba M, Tsukagoshi S (1991) Antitumor activities and schedule dependence of orally administered MST-16, a novel derivative of bis(2,6-dioxopiperazine). Cancer Chemother Pharmacol 28, 235-240
81. 81 Hellmann K, Field EO (1970) Effect of ICRF 159 on the mammalian cell cycle: significance for its use in cancer chemotherapy. J Natl Cancer Inst 44, 539-543
82. 82 Furue H, Niitani H, Nakao I, Hoshino A, Hasegawa K, Tsukagoshi S, Fujita H (1990) Phase I study of MST-16, Sobuzoxane). Cancer Chemother (in Japanese) 17, 1287-1294
83. 83 Ohno R, Yamada K, Hirano M, Shirakawa S, Tanaka M, Oguri T, Kodera Y, Mitomo Y, Ikeda Y, Yokomaku S, Kamiya O, Kobayashi M, Saito H, Kimura K, The Tokai Blood Cancer Study Group (1992) Phase II study: treatment of non-Hodgkin's lymphoma with an oral antitumor derivative of bis(2,6-dioxopiperazine). J Natl Cancer Inst 84, 435-438
84. 84 Flannery EP, Corder MP, Sheehan WW, Pajak TF, Bateman JR (1978) Phase II study of ICRF-159 in non-Hodgkin's lymphomas. Cancer Treat Rep 62, 465-467
85. 85 Ohno R, Masaoka T, Shirakawa S, Sakamoto S, Hirano M, Hanada S, Yasunaga K, Yokomaku S, MItomo Y, Nagi K, Yamada K, Furue H for the MST-16 Study Group (1993) Treatment of adult T-cell leukemia/lymphoma with MST-16, a new oral antitumor drug and a derivative of bis(2,6-dioxopiperazine). Cancer 71, 2217-2221
86. 86 Jensen PB, Sehested M (1997) DNA topoisomerase II rescue by catalytic inhibitors: A new strategy to improve the antitumor selectivity of etoposide. Biochem Pharmacol, in press
87. 87 Kagami Y, Ariyoshi Y, Horiuchi A, Kanamaru A, Kano Y, Naoe T, Oguro M, Ohno R, Sampi K, Shirakawa S, Masaoka T, Furue H, for the MST-16 Study Group (1996) Feasibility of salvage chemotherapy for refractory or relapsed non-Hodgkin's lymphoma with two topoisomerase II inhibitors, MST-16 and VP-16. Int J Hematol 64, 221-229
88. 88 Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H (1990) Doxorubicin (Adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther 47, 219-231
89. 89 Shipp NG, Dorr RT, Alberts DS, Dawson BV, Hendrix M (1993) Charcterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells. Cancer Res 53, 550-556
90. 90 Rajagopalan S, Politi PM, Sinha BK, Myers CE (1988) Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res 48, 4766-4769
91. 91 Bastra J, Wolf CR, Brown JR, Patterson LH (1985) Evidence for human liver mediated free-radical formation by doxorubicin and mitoxantrone. Anticancer Drug Design 1, 45-52
92. 92 Myers CE, Gianni L, Simone CB, Klecker R, Green R (1982) Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron omplex. Biochemistry 21, 1707-1713
93. 93 Novak RF, Kharasch ED (1985) Mitoxantrone: propensity for free radical formation and lipid peroxidation-implications for cardiotoxicity. Invest New Drugs 3, 95-99
94. 94 Green MD, Alderton P, Gross J, Muggia FM, Speyer JL (1990) Evidence of the selective alteration of anthracycline activity due to modulation by ICRF-187 (ADR-529). Pharmacol Ther 48, 61-69
95. 95 Anderson HJ, Roberge M (1996) Topoisomerase II inhibitors affect entry into mitosis and chromosome condensation in BHK cells. Cell Growth Differ 7, 83-90
96. 96 Holm B, Jensen PB, Sehested M, Hansen HH (1994) In vivo inhibition of etoposide-mediated apoptosis, toxicity, and antitumor effect by the topoisomerase II-uncoupling anthracycline aclarubicin. Cancer Chemother Pharmacol 34, 503-508